Pancreatic Cancer: Disease and Pipeline Analysis - WFXG FOX54 Augusta - Your News One Hour Earlier

Pancreatic Cancer: Disease and Pipeline Analysis

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, Ireland, January 31, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/sbps4g/pancreatic) has announced the addition of the "Pancreatic Cancer: Disease and Pipeline Analysis" report to their offering.
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

This report provides insight into a market with few effective therapies.

ISR's latest report profiles the pancreatic cancer market because it is one in which few effective therapies are currently available and has a healthy clinical development pipeline, explained Andrew Schafer, President of ISR. The market data in this report is valuable for pharmaceutical and biopharmaceutical executives looking to optimize and benchmark their clinical development programs and better guide their commercial strategies by understanding the current and future competitive landscape.

The report provides a thorough overview of the disease, provides incidence figures for all major and emerging markets, profiles the clinical development status of over 60 potential new therapies, and discusses market specific drug approval dynamics, such as localized trial and recruitment environments, regulatory environments, competitive product landscape, and pricing and reimbursement environments.

Pancreatic cancer affects a relatively small number of people around the world, which in most markets classify it as an orphan' or rare disease, Schafer explained. This classification means favorable market conditions for pharmaceutical and biopharmaceutical sponsors willing to invest in new therapies in the form of tax breaks and market exclusivity upon regulatory approval.

The report is based on data compiled by ISR analysts in the first quarter of 2013.


Key Topics Covered:

Chapter 1. Pancreatic Cancer Overview

Chapter 2. Commercial Rationale

Chapter 3. Environmental Analysis

Chapter 4. Clinical Development Pipeline

Chapter 5. Clinical Trial Environment

For more information visit http://www.researchandmarkets.com/research/sbps4g/pancreatic


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow